The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from ...

GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.

Daiichi Sankyo CEO Hiroyuki Okuzawa described the initial launch of AstraZeneca-partnered Datroway as “smooth.” After a Japanese nod in December and an FDA approval in January, the TROP2 ...

Daiichi Sankyo and AstraZeneca's TROP2-directed ADC Datroway is off to a "smooth market launch,” according to Daiichi CEO Hiroyuki Okuzawa.

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) FY2024 Earnings Conference Call April 25, 2025 2:00 AM ETCompany Participants. Kentaro Asakura - VP of Corporate Communications Hiroyuki Okuzawa ...

Daiichi Sankyo promoted Hiroyuki Okuzawa as CEO, succeeding Sunao Manabe, DVM, PhD on April 1, 2025. Astellas’ chief commercial officer Claus Zieler is set to take up the new role of chief commercial ...

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sunao Manabe, DVM, PhD, will continue to serve as representative director and ...

Daiichi Sankyo names Hiroyuki Okuzawa as CEO Written by Ruchika Sharma Published On 2025-02-03T13:30:20+05:30 | Updated On 3 Feb 2025 1:30 PM IST Tokyo: Daiichi Sankyo Company , Ltd has appointed ...

Hiroyuki Okuzawa, current COO and incoming CEO of Daiichi Sankyo, talks about the pharmaceutical company's product pipeline, including its cancer treatments, and its global partnerships with ...

Japanese drugmaker Daiichi Sankyo (TYO: 4568) has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025. Dr Manabe will transition from his current role ...